SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Mick Mørmøny who wrote (4175)7/10/1998 11:04:00 AM
From: Anthony Wong  Respond to of 9523
 
Pfizer Inc. Maintained Near-Term 'Buy' at Merrill & Salomon Smith Barney

Bloomberg News
July 10, 1998, 7:57 a.m. ET

Princeton, New Jersey, July 10 (Bloomberg Data) -- Pfizer Inc. (PFE US)
was maintained near-term ''buy'' by analyst Steven C. Tighe at Merrill Lynch &
Co. The long-term rating is also ''buy.''

-- Andrew Bekoff in Princeton, New Jersey, (609)279-3652

Bloomberg News
July 10, 1998, 8:34 a.m. ET

Princeton, New Jersey, July 10 (Bloomberg Data) -- Pfizer Inc. (PFE US)
was maintained ''buy'' by analyst Christina Heuer at Salomon Smith Barney.
The 12-month target price is $155.00 per share.

-- Andrew Bekoff in Princeton, New Jersey, (609)279-3652



To: Mick Mørmøny who wrote (4175)7/10/1998 11:06:00 AM
From: Anthony Wong  Respond to of 9523
 
Pfizer Inc. Maintained 'Attractive' at PaineWebber

Bloomberg News
July 10, 1998, 8:01 a.m. ET

Princeton, New Jersey, July 10 (Bloomberg Data) -- Pfizer Inc. (PFE US)
was maintained ''attractive'' by analyst Jeffrey Chaffkin at PaineWebber Inc.
The 12-month target price is $130.00 per share.

-- Andrew Bekoff in Princeton, New Jersey, (609)279-3652